| | Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
Pfizer snags world-first atopic dermatitis nod for Xeljanz follow-up Cibinqo amid FDA safety delay Women’s health app Flo picks up $50M in fresh funding to fuel R&D, rapid growth Researchers pinpoint autoimmune antibodies that may predict COVID-19 severity Hims & Hers drafts Super Bowl star Rob Gronkowski to drive men's health awareness OrbiMed, Lilly Asia Ventures chip into ADARx’s $75M round to take RNA tech into the clinic Health workers' licenses at risk if they spread COVID-19 vaccine misinformation Amgen's high-profile cancer med Lumakras set for rollout in England thanks to NHS access deal Novocure scores breakthrough label for liver tumor-treating electric fields and plans Avastin, Tecentriq combo studies HHS releases $25.5B in COVID-19 relief funding targeted at smaller providers COVID-19 tracker: Unvaccinated people 11 times more likely to die than vaccinated, CDC says SCAN Health Plan eyes expansion into Nevada, Arizona for 2022 Chutes & Ladders—Former FDA Commissioner Hahn takes interim CMO role at YourBio Health Featured Story | By Angus Liu As the FDA delays decisions on several JAK inhibitors over safety concerns, its U.K. counterpart has moved forward to grant a new Pfizer drug its first approval worldwide. read more |
| |
|---|
|
Top Stories By Emmy Lucas The women's health app Flo's valuation increased to $800 million after its series B funding round. read more By Kyle LaHucik NYU researchers reported that in the early days of the pandemic, they found certain autoimmune antibodies in hospitalized patients that correlated to more severe COVID-19 disease. They believe their findings could be used to help hospitals determine how best to treat patients admitted with COVID-19. read more By Beth Snyder Bulik Notoriously laid-back NFL star Rob Gronkowski is looking to score for the telehealth and medication delivery service Hims & Hers Health with messages on social media, digital, TV and streaming audio. read more By Emmy Lucas OrbiMed Advisors and Lilly Asia Ventures are two key players pouring money into RNA-targeting technology via ADARx Pharmaceuticals’ $75 million series B round. The funding will take the San Diego-based biotech’s growing pipeline of RNA-targeting therapeutics into the clinic, ADARx said in a statement on Wednesday. read more By Anastassia Gliadkovskaya The American Board of Family Medicine, the American Board of Internal Medicine and the American Board of Pediatrics announced in a joint statement that board-certified physicians may lose their license if they spread misleading information about the COVID-19 vaccines. read more By Eric Sagonowsky Only months after Amgen kicked off its U.S. launch for cancer drug Lumakras, the med is set to make its debut in England. read more By Conor Hale Novocure hopes to put forward its therapy as a first-line option for unresectable or metastatic liver cancer. read more By Robert King HHS announced a $25.5 billion distribution of COVID-19 relief funds, the first distribution announcement in nearly a year. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The CDC says unvaccinated Americans are 11 times more likely to die than those who are vaccinated. Moderna's shot is slightly more effective at preventing hospitalizations. Plus more. read more By Paige Minemyer Medicare Advantage insurer SCAN Health Plan will expand its coverage options into Arizona and Nevada for the 2022 plan year, the company announced Thursday. read more By Kyle LaHucik Former FDA Commissioner Stephen Hahn is joining YourBio Health as interim chief medical officer. Gilead's global head of liver diseases, Tram Tran, M.D., will be Glympse Bio's first chief medical officer. And Orchard Therapeutics picks an apple from Novartis' field, snagging cell and gene therapies leader Nicoletta Loggia, Ph.D., as chief technical officer. read more |
